DE69124598T2 - Synergistische therapeutische zusammensetzungen und verfahren - Google Patents

Synergistische therapeutische zusammensetzungen und verfahren

Info

Publication number
DE69124598T2
DE69124598T2 DE69124598T DE69124598T DE69124598T2 DE 69124598 T2 DE69124598 T2 DE 69124598T2 DE 69124598 T DE69124598 T DE 69124598T DE 69124598 T DE69124598 T DE 69124598T DE 69124598 T2 DE69124598 T2 DE 69124598T2
Authority
DE
Germany
Prior art keywords
methods
therapeutic compositions
synergistic therapeutic
synergistic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69124598T
Other languages
English (en)
Other versions
DE69124598D1 (de
Inventor
Anthony FOSSA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69124598(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69124598D1 publication Critical patent/DE69124598D1/de
Application granted granted Critical
Publication of DE69124598T2 publication Critical patent/DE69124598T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69124598T 1990-05-11 1991-04-22 Synergistische therapeutische zusammensetzungen und verfahren Expired - Lifetime DE69124598T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11
PCT/US1991/002733 WO1991017771A1 (en) 1990-05-11 1991-04-22 Synergistic therapeutic compositions and methods

Publications (2)

Publication Number Publication Date
DE69124598D1 DE69124598D1 (de) 1997-03-20
DE69124598T2 true DE69124598T2 (de) 1997-05-28

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124598T Expired - Lifetime DE69124598T2 (de) 1990-05-11 1991-04-22 Synergistische therapeutische zusammensetzungen und verfahren

Country Status (34)

Country Link
US (2) US6900234B1 (de)
EP (1) EP0527879B1 (de)
JP (2) JPH0729938B2 (de)
KR (1) KR970005839B1 (de)
CN (7) CN1879884A (de)
AP (1) AP240A (de)
AT (1) ATE148632T1 (de)
AU (1) AU653724B2 (de)
BG (1) BG61831B1 (de)
BR (1) BR9106438A (de)
CA (1) CA2081564C (de)
DE (1) DE69124598T2 (de)
DK (1) DK0527879T3 (de)
EG (1) EG19648A (de)
ES (1) ES2097208T3 (de)
GR (1) GR3022997T3 (de)
GT (1) GT199100032A (de)
HK (1) HK1094148A1 (de)
HU (1) HU227346B1 (de)
IE (1) IE911592A1 (de)
IL (1) IL98055A (de)
IS (1) IS2042B (de)
MA (1) MA22150A1 (de)
MY (1) MY114347A (de)
NO (1) NO924321L (de)
NZ (1) NZ238118A (de)
PE (1) PE30891A1 (de)
PT (1) PT97615B (de)
RO (1) RO115786B1 (de)
RU (1) RU2147875C1 (de)
TW (1) TW203553B (de)
WO (1) WO1991017771A1 (de)
YU (1) YU49094B (de)
ZA (1) ZA913539B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
SK133897A3 (en) * 1995-04-07 1998-02-04 Ciba Geigy Ag Combination compositions containing benazepril or benazeprilat and valsartan
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
NZ330774A (en) 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
DE69712338T2 (de) * 1996-06-24 2002-11-07 Merck & Co Inc Zusammensetzung auf basis von enalapril und losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1999015643A2 (en) * 1997-09-25 1999-04-01 University Of Florida ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
DK1047450T3 (da) * 1997-12-23 2003-01-27 Warner Lambert Co Kombinationer af ACE-inhibitorer og MMP-inhibitorer
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
ES2527870T5 (es) 2003-04-08 2022-10-14 Progenics Pharm Inc Formulaciones farmacéuticas que contienen metilnaltrexona
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
PT1799199E (pt) * 2004-10-08 2012-07-03 Novartis Ag Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TWI466671B (zh) 2007-03-29 2015-01-01 Progenics Pharm Inc 末梢性類鴉片受體拮抗劑及其用途
EP3263571B2 (de) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Kristallform von (r)-n-methylnaltrexonebromide und verwendungen davon
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
CA2081564C (en) * 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods

Also Published As

Publication number Publication date
CN101156949A (zh) 2008-04-09
ES2097208T3 (es) 1997-04-01
MY114347A (en) 2002-10-31
EG19648A (en) 1995-09-30
BG61831B1 (bg) 1998-07-31
BR9106438A (pt) 1993-05-18
IE911592A1 (en) 1991-11-20
HU9203522D0 (en) 1993-01-28
AP9100258A0 (en) 1991-07-31
TW203553B (de) 1993-04-11
JPH05505618A (ja) 1993-08-19
RU2147875C1 (ru) 2000-04-27
US6716875B1 (en) 2004-04-06
US6900234B1 (en) 2005-05-31
HUT62804A (en) 1993-06-28
WO1991017771A1 (en) 1991-11-28
CN1879884A (zh) 2006-12-20
PE30891A1 (es) 1991-11-27
CN100358578C (zh) 2008-01-02
HU227346B1 (en) 2011-04-28
MA22150A1 (fr) 1991-12-31
IL98055A (en) 1996-10-31
EP0527879B1 (de) 1997-02-05
CA2081564A1 (en) 1991-11-12
NO924321L (no) 1993-01-08
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
DK0527879T3 (da) 1997-07-14
GT199100032A (es) 1992-10-31
AU7859191A (en) 1991-12-10
CN1065140C (zh) 2001-05-02
YU81991A (sh) 1994-06-24
YU49094B (sh) 2003-12-31
JPH0748280A (ja) 1995-02-21
ZA913539B (en) 1992-12-30
AU653724B2 (en) 1994-10-13
CN1056426A (zh) 1991-11-27
NZ238118A (en) 1997-06-24
CN1307901A (zh) 2001-08-15
KR970005839B1 (ko) 1997-04-21
IL98055A0 (en) 1992-06-21
CN1502370A (zh) 2004-06-09
DE69124598D1 (de) 1997-03-20
IS2042B (is) 2005-09-15
CN1824315B (zh) 2011-01-12
CN1915428A (zh) 2007-02-21
IS3703A7 (is) 1991-11-12
PT97615B (pt) 1998-08-31
EP0527879A1 (de) 1993-02-24
NO924321D0 (no) 1992-11-10
AP240A (en) 1993-02-18
RO115786B1 (ro) 2000-06-30
ATE148632T1 (de) 1997-02-15
PT97615A (pt) 1992-03-31
JP2635291B2 (ja) 1997-07-30
GR3022997T3 (en) 1997-07-30
JPH0729938B2 (ja) 1995-04-05
HK1094148A1 (en) 2007-03-23

Similar Documents

Publication Publication Date Title
DE69124598D1 (de) Synergistische therapeutische zusammensetzungen und verfahren
NO941929L (no) Tokotrienoler og tokotrienol-lignende sammensetninger og fremgangsmåter for deres anvendelse
DE69230954D1 (de) Modulare Schnittstelle und Verfahren hierfür
DE69324942T2 (de) Strahlungsempfindliche Zusammensetzungen und Verfahren
DE68918943T2 (de) Gewebeentzusammensetzung und verfahren.
DE69211276D1 (de) Verfahren und Schleifvorrichtung
DE68928033D1 (de) Stereosynthesizer und entsprechendes verfahren
BR1100824A (pt) Composto e composição farmacêutica
DE69212502T2 (de) Klebstoffzusammensetzung und verfahren
FI951197A (fi) Mikrobisidiset koostumukset ja menetelmät
NO933601D0 (no) Forbedret ligningsbasert treklebemiddel
HU9400190D0 (en) Therapeutic compositions and methods
ITTO910114A0 (it) Composizioni e procedimenti di placcatura
DE69605094D1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
NO912773D0 (no) Antitumor-sammensetninger og fremgangsmaater for behandling
DE69024818T2 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
ITMI931125A0 (it) Composizioni dentarie e di ricostruzione
BR8905444A (pt) Composicoes e aplicacao
DE69213415T2 (de) Elektroplattierungszusammensetzung und Verfahren
FI934360A0 (fi) Synergistiska antimalariakompositioner innehaollande benflumetol
IT1243911B (it) Composizioni per la terapia mucolitica
DE69115602T2 (de) Haarbehandlungszusammensetzung
NO923082L (no) Terapeutiske midler
BR9006458A (pt) Combinacao fungicida de efeito sinergico e composicao fungicida
SE9200780D0 (sv) Composition for therapeutic use

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings